Peter M Siegel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5061722/publications.pdf

Version: 2024-02-01

94 papers	14,166 citations	66343 42 h-index	43889 91 g-index
97 all docs	97 docs citations	97 times ranked	20980 citing authors

#	Article	IF	Citations
1	HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin. Oncogene, 2022, 41, 1701-1717.	5.9	8
2	Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. Cell Reports, 2022, 39, 110634.	6.4	10
3	Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. British Journal of Cancer, 2022, 127, 988-1013.	6.4	30
4	Afadin (AF6) in cancer progression: A multidomain scaffold protein with complex and contradictory roles. BioEssays, 2021, 43, e2000221.	2.5	9
5	The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers. Cancers, 2021, 13, 732.	3.7	14
6	Creatine-mediated crosstalk between adipocytes and cancer cells regulates obesity-driven breast cancer. Cell Metabolism, 2021, 33, 499-512.e6.	16.2	61
7	Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. ELife, 2021, 10, .	6.0	23
8	Claudin-2 promotes colorectal cancer liver metastasis and is a biomarker of the replacement type growth pattern. Communications Biology, 2021, 4, 657.	4.4	32
9	STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nature Communications, 2021, 12, 3299.	12.8	24
10	Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases. Communications Biology, 2021, 4, 950.	4.4	26
11	Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases. Neuro-Oncology, 2021, 23, 1470-1480.	1.2	18
12	Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis. Journal of Clinical Investigation, 2021, 131, .	8.2	15
13	Neutrophils: Orchestrators of the Malignant Phenotype. Frontiers in Immunology, 2020, 11, 1778.	4.8	20
14	Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors. Communications Biology, 2020, 3, 310.	4.4	28
15	p66ShcA functions as a contextual promoter of breast cancer metastasis. Breast Cancer Research, 2020, 22, 7.	5.0	10
16	The SHCA adapter protein cooperates with lipoma-preferred partner in the regulation of adhesion dynamics and invadopodia formation. Journal of Biological Chemistry, 2020, 295, 10535-10559.	3.4	10
17	C3a elicits unique migratory responses in immature low-density neutrophils. Oncogene, 2020, 39, 2612-2623.	5.9	20
18	Optimizing live-cell fluorescence imaging conditions to minimize phototoxicity. Journal of Cell Science, 2020, 133, .	2.0	51

#	Article	IF	Citations
19	CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro. Scientific Reports, 2019, 9, 16317.	3.3	19
20	Afadin cooperates with Claudin-2 to promote breast cancer metastasis. Genes and Development, 2019, 33, 180-193.	5.9	45
21	CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis. American Journal of Pathology, 2019, 189, 1451-1461.	3.8	9
22	Immature Low-Density Neutrophils Exhibit Metabolic Flexibility that Facilitates Breast Cancer Liver Metastasis. Cell Reports, 2019, 27, 3902-3915.e6.	6.4	144
23	High Throughput Traction Force Microscopy Using PDMS Reveals Dose-Dependent Effects of Transforming Growth Factor-β on the Epithelial-to-Mesenchymal Transition. Journal of Visualized Experiments, 2019, , .	0.3	15
24	GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and Î²-catenin activity. Oncogene, 2019, 38, 5294-5307.	5.9	22
25	Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis. Translational Oncology, 2019, 12, 462-474.	3.7	66
26	EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours. Oncogene, 2018, 37, 4073-4093.	5.9	30
27	Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene, 2018, 37, 3183-3199.	5.9	317
28	Emerging roles for LPP in metastatic cancer progression. Journal of Cell Communication and Signaling, 2018, 12, 143-156.	3.4	25
29	GPNMB methylation: a new marker of potentially carcinogenic colon lesions. BMC Cancer, 2018, 18, 1068.	2.6	5
30	A Three-Dimensional Dense Collagen Hydrogel to Model Cancer Cell/Osteoblast Interactions. Journal of Functional Biomaterials, 2018, 9, 72.	4.4	23
31	Translational and HIF-1Î±-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. Cell Metabolism, 2018, 28, 817-832.e8.	16.2	61
32	Metabolic Profiles Associated With Metformin Efficacy in Cancer. Frontiers in Endocrinology, 2018, 9, 372.	3.5	61
33	LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis. Science, 2018, 361, 406-411.	12.6	47
34	Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion. Breast Cancer Research, 2018, 20, 9.	5.0	23
35	DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy. Anti-Cancer Drugs, 2018, 29, 774-785.	1.4	12
36	Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Clinical Cancer Research, 2018, 24, 6483-6494.	7.0	55

#	Article	IF	Citations
37	Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinations. , 2018, , .		1
38	LPP is a Src substrate required for invadopodia formation and efficient breast cancer lung metastasis. Nature Communications, 2017, 8, 15059.	12.8	59
39	Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer. , 2017, 179, 127-141.		64
40	Expanding the armamentarium for neutrophilâ€mediated angiogenesis. Hepatology, 2017, 65, 1796-1798.	7.3	1
41	Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration. Journal of Bone Oncology, 2017, 6, 8-15.	2.4	9
42	PGC-1Î± Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. Cell Metabolism, 2017, 26, 778-787.e5.	16.2	181
43	The role of claudins in cancer metastasis. Oncogene, 2017, 36, 1176-1190.	5.9	140
44	Future directions for bone metastasis research â€“ highlights from the 2015 bone and the Oncologist new updates conference (BONUS). Journal of Bone Oncology, 2016, 5, 57-62.	2.4	9
45	Targeting tumor microenvironment in cancer therapy. Cancer Letters, 2016, 380, 203-204.	7.2	39
46	5â€²-Inositol phosphatase SHIP2 recruits Mena to stabilize invadopodia for cancer cell invasion. Journal of Cell Biology, 2016, 214, 719-734.	5.2	27
47	Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis. Cancer Research, 2016, 76, 5201-5208.	0.9	214
48	MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Clinical Cancer Research, 2016, 22, 6088-6098.	7.0	43
49	The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness. Journal of Cellular Biochemistry, 2016, 117, 1971-1990.	2.6	11
50	Featuring the guest editors: Special issue tumor microenvironment. Cancer Letters, 2016, 380, 201-202.	7.2	0
51	The influence of the pre-metastatic niche on breast cancer metastasis. Cancer Letters, 2016, 380, 281-288.	7.2	45
52	Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion. Molecular and Cellular Biology, 2016, 36, 1509-1525.	2.3	53
53	The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L. ELife, 2016, 5, .	6.0	23
54	Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. Breast Cancer Research, 2015, 17, 45.	5.0	103

#	Article	IF	Citations
55	Decreased PCSK9 expression in human hepatocellular carcinoma. BMC Gastroenterology, 2015, 15, 176.	2.0	46
56	Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis. Oncotarget, 2015, 6, 9476-9487.	1.8	47
57	Peroxiredoxin 4: A novel secreted mediator of cancer induced osteoclastogenesis. Cancer Letters, 2015, 361, 262-270.	7.2	32
58	GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin Î±5Î²1 for efficient breast cancer metastasis. Oncogene, 2015, 34, 5494-5504.	5.9	61
59	The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis. Molecular Cancer Therapeutics, 2015, 14, 982-993.	4.1	34
60	PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer. Cell Metabolism, 2015, 22, 577-589.	16.2	430
61	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 2014, 46, 462-466.	21.4	381
62	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nature Genetics, 2014, 46, 39-44.	21.4	167
63	Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3619-3625.	1.6	94
64	LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer & Metabolism, 2013, 1, 18.	5.0	44
65	AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth InÂVivo. Cell Metabolism, 2013, 17, 113-124.	16.2	754
66	Distinct Phosphotyrosine-dependent Functions of the ShcA Adaptor Protein Are Required for Transforming Growth Factor Î² (TGFÎ²)-induced Breast Cancer Cell Migration, Invasion, and Metastasis. Journal of Biological Chemistry, 2013, 288, 5210-5222.	3.4	19
67	A complex containing LPP and Î±-Actinin mediates TGFÎ²-induced migration and invasion of ErbB2-expressing breast cancer cells. Journal of Cell Science, 2013, 126, 1981-91.	2.0	37
68	The ShcA PTB Domain Functions as a Biological Sensor of Phosphotyrosine Signaling during Breast Cancer Progression. Cancer Research, 2013, 73, 4521-4532.	0.9	13
69	Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. OncoTargets and Therapy, 2013, 6, 839.	2.0	95
70	ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Research, 2012, 14, R149.	5.0	40
71	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	27.8	2,129
72	Claudin-2 Promotes Breast Cancer Liver Metastasis by Facilitating Tumor Cell Interactions with Hepatocytes. Molecular and Cellular Biology, 2012, 32, 2979-2991.	2.3	89

#	Article	IF	Citations
73	CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis. Journal of Cell Communication and Signaling, 2012, 6, 73-85.	3.4	33
74	CCN3 Impairs Osteoblast and Stimulates Osteoclast Differentiation to Favor Breast Cancer Metastasis to Bone. American Journal of Pathology, 2011, 178, 2377-2388.	3.8	54
75	Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene, 2011, 30, 1318-1328.	5.9	130
76	Transcription factor regulatory networks in mammary epithelial development and tumorigenesis. Oncogene, 2010, 29, 2753-2759.	5.9	39
77	ADAM10 Releases a Soluble Form of the GPNMB/Osteoactivin Extracellular Domain with Angiogenic Properties. PLoS ONE, 2010, 5, e12093.	2.5	149
78	Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer. Clinical Cancer Research, 2010, 16, 2147-2156.	7.0	172
79	Emerging therapeutic targets in breast cancer bone metastasis. Future Oncology, 2010, 6, 55-74.	2.4	63
80	A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC). Journal of Clinical Oncology, 2009, 27, 1067-1067.	1.6	3
81	Osteoclast precursors acquire sensitivity to breast cancer derived factors early in differentiation. Bone, 2008, 43, 386-393.	2.9	39
82	Signaling through ShcA Is Required for Transforming Growth Factor Î²- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion. Molecular and Cellular Biology, 2008, 28, 3162-3176.	2.3	61
83	Osteoactivin Promotes Breast Cancer Metastasis to Bone. Molecular Cancer Research, 2007, 5, 1001-1014.	3.4	146
84	Genes that mediate breast cancer metastasis to lung. Nature, 2005, 436, 518-524.	27.8	2,581
85	A multigenic program mediating breast cancer metastasis to bone. Cancer Cell, 2003, 3, 537-549.	16.8	2,325
86	Transforming growth factor Î² signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8430-8435.	7.1	409
87	Mad Upregulation and Id2 Repression Accompany Transforming Growth Factor (TGF)-Î²-mediated Epithelial Cell Growth Suppression. Journal of Biological Chemistry, 2003, 278, 35444-35450.	3.4	85
88	Mammary gland neoplasia: insights from transgenic mouse models. BioEssays, 2000, 22, 554-563.	2.5	40
89	Oncogenic Activating Mutations in the neu/erbB-2 Oncogene Are Involved in the Induction of Mammary Tumors. Annals of the New York Academy of Sciences, 1999, 889, 45-51.	3.8	23
90	Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO Journal, 1999, 18, 2149-2164.	7.8	389

#	Article	IF	Citations
91	Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 8878-8883.	7.1	91
92	Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors.. Molecular and Cellular Biology, 1994, 14, 7068-7077.	2.3	188
93	Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Molecular and Cellular Biology, 1994, 14, 735-743.	2.3	96
94	Novel Activating Mutations in the neu Proto-oncogene Involved in Induction of Mammary Tumors. Molecular and Cellular Biology, 1994, 14, 7068-7077.	2.3	124